Table 1 Demographic, baseline and on-treatment characteristics of female and male patients with any health-related quality of life data
Variable | Total | Female | Male | P-value |
|---|---|---|---|---|
Number | 295 | 219 | 76 | - |
Age (years) (mean, (SD) | 34 (7) | 33 (7) | 38 (6) | <0.001 |
WHO stage 3 & 4 (n,(%)) | 254 (86) | 184 (86) | 70 (92) | 0.079 |
Baseline CD4 count cells/mm3 (median, (IQR)) | 88 (47; 148) | 96 (52; 159) | 77 (36; 130) | 0.027 |
Baseline viral load copies/ml (median, (IQR)) | 80,876 (33,194; 201,784) | 76,452 (31,547; 198,193) | 87,763 (42,884; 211,938) | 0.216 |
Baseline viral load log copies/ml (median, (IQR)) | 4.88 (4.52; 5.30) | 4.88 (4.50; 5.30) | 4.94 (4.63; 5.32) | 0.216 |
Week 48 CD4 count cells/mm3 (median, (IQR)) | 261 (183; 340) | 265 (205; 365) | 215 (171; 304) | 0.004 |
Week 48 viral load copies/ml (median,(IQR)) | 49 (49; 49) | 49 (49; 49) | 49 (49; 49) | 0.340 |
Week 48 viral load log copies/ml (median,(IQR)) | 1.69 (1.69; 1.69) | 1.69 (1.69; 1.69) | 1.69 (1.69; 1.69) | 0.276 |
Change in CD4 count cells/mm3 (mean, (SD)) | 178 (130) | 184 (136) | 159 (107) | 0.152 |
Change in viral load log copies/ml (mean, (SD)) | -2.96 (0.91) | -2.91 (0.95) | -3.11 (0.75) | 0.107 |
Drug toxicity (n, (%)) | 11 (4%) | 10 (5%) | 1 (1%) | 0.198 |